The treatment of non–muscle-invasive bladder cancer (NMIBC) is rapidly evolving, according to Philippe E. Spiess, MD, MS, FRCS(C), Assistant Chief of Surgical Services, and Senior Member in the Department of Genitourinary Oncology, Moffitt Cancer Center. “It’s critical for all healthcare providers who see patients with bladder cancer to become familiar with and refer to the NCCN Guidelines on a regular basis because they are continuously updated,” he said at the NCCN 2020 Virtual Annual Conference. “They are evidence-based, taking only the most rigorous, robust data for integration and adoption in the treatment of our patients.”
Perhaps the most important update to the NCCN Guidelines in NMIBC is the addition of pembrolizumab for recurrent or persistent disease, particularly in patients with bacillus Calmette-Guérin (BCG)–unresponsive high-risk NMIBC specifically with carcinoma in situ with or without papillary bladder tumors. Other topical issues in the field include recently standardized definitions for patients unresponsive to BCG (the most commonly used intravesical immunotherapy for treating early-stage bladder cancer), as well as potential ramifications of an ongoing BCG shortage.
American Cancer Society. Key Statistics for Bladder Cancer. Revised January 8, 2020. Accessed June 11, 2020. Available at: https://www.cancer.org/cancer/bladder-cancer/about/key-statistics.html
Flaig TW, Spiess PE, Agarwal N, NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer. Version 3.2020. Accessed January 17, 2020. Available at NCCN.org
Chang SS, Boorjian SA, Chou R, Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol 2016;196:1021–1029.
Babjuk M, Burger M, Compérat EM, European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)—2019 update. Eur Urol 2019;76:639–657.
Khanna A, Yerram N, Zhu H, Utilization of bacillus Calmette-Guerin for nonmuscle invasive bladder cancer in an era of bacillus Calmette-Guerin supply shortages. Urology 2019;124:120–126.
Bandari J, Maganty A, MacLeod LC, Manufacturing and the market: rationalizing the shortage of bacillus Calmette-Guérin. Eur Urol Focus 2018;4:481–484.
Kamat AM, Sylvester RJ, Böhle A, Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. J Clin Oncol 2016;34:1935–1944.
- Search Google Scholar
- Export Citation
)| false , Kamat AM , Sylvester RJ , Böhle A Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. J Clin Oncol 2016; 34: 1935– 1944. 26811532 10.1200/JCO.2015.64.4070